Subsequently, a multicenter, double-blind, randomized Phase II clinical trial involving 265 patients with high-grade serous ovarian cancer and BRCA1/2 germline mutations revealed that progression-free survival (PFS) was significantly longer in the Olaparib group (8.4 months) compared to the placebo group (4.8 months) (62). This evidence concerns the gene BRCA1 and ovarian serous adenocarcinoma.